A recorder is available during non-working h ours. TREATMENT ASSIGNMENT PROCEDURES 2.4.1 CohortsSubjects will be enrolle d in one of two cohorts: Number Name Description 1 Melanoma Patients with met astatic melanoma 2 Epithelial Patients with epithelial cancer 2.4.2 Arms Number Name Description 1Experimental TherapyPeptide loaded dendritic cell vaccine on days 0, 14, 28, and 42 2.4.3 Randomization and Arm Assignment This is a non-randomized study. All subjects will be directly a ssigned based on cohort as follows: xSubjects in Cohorts 1-2 will be di rectly assigned to Arm 1. Abbreviated Title: Personalized DC Vaccine Version Date: March 26, 2018 163 STUDY IMPLEMENTATION STUDY DESIGN 3.1.1 Pre-Treatment Pha se: DC Preparation Tumor Harvest or possible apheresis Initial Growth of Cells Sequencing  Identification of mutations  Manufacture peptides Cryo preserve cellsPatient Apheresis  Manufacture Dendritic Cells  Cryo-preserve DCs  Thaw DCs  Pulse with identified peptides  Mature DCs  Prepare final product Administer Vaccines 1 (day 0) Thaw cells  Test reactivity of peptides  Identify peptides Order GLP Peptides6-8 weeks 5-6 weeksReceive GLP Peptides  Thaw DCs  Pulse with identified peptides  Mature DCs  Prepare final product Administer Vaccines 2 (~day 14) Thaw DCs  Pulse with identified peptides  Mature DCs  Prepare final product Administer Vaccines 3 (~day 28) Thaw DCs  Pulse with identified peptides  Mature DCs  Prepare final product Administer Vaccines 4 (~day 42)3 days Under 03-C-0277, patients with evaluable metas tatic melanoma or epithelial cancers will undergo resection of the tumor a nd apheresis. Whole exome and RNA sequencing will be performed to identify all cancer mutations using our standard procedures.